| HALOZYME THERAPEUTICS |
| USA |
| Gesundheit |
| US40637H1095 / A0DLHS |
| RV7 (Frankfurt) |
| FRA:RV7, ETR:RV7, RV7:GR |
| - |
| https://halozyme.com/ |
|
Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), en..
>Volltext.. |
| 6642.69 Mio. EUR |
| 8366.57 Mio. EUR |
| 1188.8 Mio. EUR |
| 769.78 Mio. EUR |
| 269.74 Mio. EUR |
| 2.22 EUR |
| 1853.23 Mio. EUR |
| 113.91 Mio. EUR |
| 554.61 Mio. EUR |
| 0.81 |
| 21.24% |
| -37.11% |
| - |
| - |
| - |
| - |
| HALOZYME |
| 07.05.26 |
|